secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-070899
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q1 neffy revenue $7.8M, net loss $33.9M; commercial progress with 5,000+ prescribers
--------------------------------------------------------------------------------

- Net product revenue of $7.8M from neffy; total revenue $8.0M; net loss $33.9M ($0.35 per share).
- Cash, equivalents and investments $275.7M; company says runway adequate for over three years.
- More than 5,000 HCPs prescribed neffy; co-promotion with ALK expands reach to ~20,000 HCPs including pediatricians.
- 57% commercial coverage secured; neffy 1mg now available for children 4+ weighing 15-30 kg.
- Regulatory decisions expected mid-2025 in UK, year-end in Canada; German launch mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/0000950170-25-070899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer